Washington, DC (April 15, 2025) – Today’s approval of Leqembi by the European Commission marks a significant milestone in the global fight to end Alzheimer’s. While the treatment is approved for early-stage patients with certain genetic markers, it represents a major step forward in bringing advanced treatment to those affected by this devastating disease.

UsAgainstAlzheimer’s Chair and Co-Founder, George Vradenburg, released the following statement: 

“Today’s decision by the European Commission to approve Leqembi for people in the early stages of Alzheimer’s disease is a victory for patients and those who love them. This treatment offers hope to patients and families facing this devastating—and ultimately fatal—disease.

“We fully support precautions to protect patients while still making it possible for them to benefit from a treatment that has been shown to slow the disease in many people. This is promising—and proof that momentum is building around the world to end Alzheimer’s.”